000007591 001__ 7591
000007591 005__ 20240124114246.0
000007591 0247_ $$2DOI$$a10.6083/gf06g318p
000007591 037__ $$aETD
000007591 245__ $$aImmune contexture of pancreatitis and pancreatic cancer: implications for immunotherapy
000007591 260__ $$bOregon Health and Science University
000007591 269__ $$a2019
000007591 336__ $$aDissertation
000007591 502__ $$bPh.D.
000007591 520__ $$aLeukocytes recruited to and persistent within chronically inflamed tissues play critical roles in fostering neoplastic progression. Immunotherapies designed to reprogram protumoral immune microenvironments have gained clinical traction in many solid tumors, but pancreatic ductal adenocarcinoma (PDAC) has thus far failed to respond to single-agent immunotherapy. Recent preclinical studies have indicated that combinatorial immunotherapy may yield improved response rates in PDAC, especially combinations intended to both reprogram immunosuppressive myeloid cells and antagonize T cell inhibitory pathways. However, the immune microenvironment of human PDAC is heterogeneous and has not been extensively characterized in situ. As such, functionally significant immune biomarkers are urgently needed to better stratify patients for appropriate immunotherapeutic combinations.
000007591 542__ $$fIn copyright - single owner
000007591 650__ $$aImmunohistochemistry$$020708
000007591 650__ $$aB-Lymphocytes$$015306
000007591 650__ $$aTumor Microenvironment$$039473
000007591 650__ $$aImmunotherapy$$020724
000007591 650__ $$aPancreatitis$$023522
000007591 6531_ $$apancreatic ductal carcinoma
000007591 691__ $$aSchool of Medicine$$041369
000007591 7001_ $$aLiudahl, Shannon M.
000007591 8564_ $$9e23e4058-0f3d-428e-bd6e-4051d57cd7a5$$s47002257$$uhttps://digitalcollections.ohsu.edu/record/7591/files/liudahl.shannon.2019.pdf
000007591 905__ $$a/rest/prod/gf/06/g3/18/gf06g318p
000007591 909CO $$ooai:digitalcollections.ohsu.edu:7591$$pstudent-work
000007591 980__ $$aTheses and Dissertations